- Conditions
- Osteoarthritis of the Knee, Type 2 Diabetes Mellitus
- Interventions
- FX006 32 mg, TCA IR 40 mg
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 8
- States / cities
- Anaheim, California • El Cajon, California • North Hollywood, California + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–21
of 21
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis, Noninfectious Uveitis
- Interventions
- triamcinolone acetonide (Triesence®)
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Omaha, Nebraska • Cleveland, Ohio
- Conditions
- Osteoarthritis of the Knee
- Interventions
- FX006 32 mg, TCA IR 40
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- Canoga Park, California • San Diego, California • Hialeah, Florida + 1 more
- Conditions
- Osteoarthritis, Knee, Diabetes Mellitus, Type 2
- Interventions
- triamcinolone acetonide extended-release injectable suspension; TCA-ER, Triamcinolone Acetonide- Immediate Release;TCA-IR
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Lumbar Radiculopathy, Sciatica, Back Pain With Radiation
- Interventions
- Triamcinolone 10 Mg/mL Injectable Suspension, Triamcinolone 40 Mg/mL Injectable Suspension, Triamcinolone 80 Mg/mL Injectable Suspension, Dexamethasone 2 MG, Dexamethasone 4mg, Dexamethasone 8 MG
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Acute Gouty Arthritis
- Interventions
- Anakinra 100 mg, Triamcinolone Acetonide 40 mg, Placebo to Anakinra 100 mg, Placebo to Triamcinolone Acetonide 40 mg
- Drug
- Lead sponsor
- Swedish Orphan Biovitrum
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 32 more
- Conditions
- Knee Osteoarthritis
- Interventions
- Triamcinolone Acetonide 40 mg/ml Inj, Susp, Platelet-rich plasma Inj
- Drug · Biological
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Shoulder Pain
- Interventions
- Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch, Triamcinolone Acetonide
- Drug
- Lead sponsor
- Injury Care Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Boise, Idaho
- Conditions
- Osteoarthritis of the Knee
- Interventions
- FX006 10 mg, FX006 40 mg, TCA IR 40 mg
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 3
- States / cities
- Paducah, Kentucky • Duncansville, Pennsylvania • Dallas, Texas
- Conditions
- Vocal Cord Disease, Vocal Cord Polyp, Vocal Cord Cyst
- Interventions
- Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension), Superior laryngeal nerve block - Placebo (saline)
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
- Interventions
- 4mg CLS-TA Suprachoriodal Injection, Sham Procedure
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 36 more
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
- Interventions
- 4 mg CLS-TA Suprachoriodal Injection
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 7 more
- Conditions
- Osteoarthritis of the Knee
- Interventions
- FX006, TCA IR
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Duncansville, Pennsylvania
- Conditions
- Knee Osteoarthritis, Musculoskeletal Disease, Surgery
- Interventions
- PAI, PAI + steroid, PAI + zilretta
- Drug
- Lead sponsor
- Walter Reed National Military Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- 4 mg CLS-TA, Sham, IVT aflibercept
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Beverly Hills, California • San Diego, California + 11 more
- Conditions
- Post-traumatic Osteoarthritis of the Knee
- Interventions
- FX006 32 mg, TCA IR 40 mg
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 20 Years to 50 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Acute Gout
- Interventions
- Canakinumab 150 mg, Triamcinolone acetonide 40 mg, Placebo to canakinumab, Placebo to triamcinolone acetonide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 96
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Foley, Alabama + 81 more
- Conditions
- Uveitis, Macular Edema, Uveitis, Posterior, Uveitis, Anterior, Panuveitis, Uveitis, Intermediate
- Interventions
- 4 mg CLS-TA, 0.8 mg CLS-TA
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 11
- States / cities
- Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Osteoarthritis of the Knee
- Interventions
- FX006, Placebo, TCA IR 40
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 486 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 17 more
- Conditions
- Tenosynovitis
- Interventions
- Treatment Group: Corticosteroid injection, Control Group (corticosteroid alone), Treatment Group: Lidocaine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Osteoarthritis
- Interventions
- Synvisc (Hylan G-F20; hyaluronan injection), Bupivicaine (local anesthesia injection), Kenalog (triamcinolone; corticosteroid injection)
- Drug
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 45 Years to 95 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York